Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
21.05. | ViroGates A/S: Resolutions from the Extraordinary General Meeting of ViroGates A/S | 73 | GlobeNewswire (Europe) | Company Announcement no. 8/2025 (May 21, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
01.05. | ViroGates A/S: ViroGates announces its Q1 report for 2025 | 34 | GlobeNewswire (Europe) | Company Announcement no. 6/2025 (May 01, 2025)
Revenue comparable to the same period last year, operating expenses reduced by 33%, and an amended agreement with Sobi
BIRKERØD, DENMARK - ViroGates A/S... ► Artikel lesen | |
20.03. | ViroGates A/S: ViroGates announces its Annual Report 2024 | 82 | GlobeNewswire (Europe) | Company Announcement no. 3/2025 (March 20, 2025)
Revenue declines by 12 % compared to last year as ViroGates continues the transition into the health- and longevity segment and fosters strategic partnerships
BIRKERØD... ► Artikel lesen | |
07.11.24 | ViroGates A/S: ViroGates announces its Interim Report for Q1-Q3 2024: Revenues are disappointing, but strategic refocusing will pave the way for future growth | 200 | GlobeNewswire (Europe) | Company Announcement no. 9/2024 (November 07, 2024)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for the measurement of chronic... ► Artikel lesen | |
06.11.24 | First North Denmark: ViroGates A/S - increase | 348 | GlobeNewswire | New shares in ViroGates A/S will be admitted to trading on Nasdaq First North
Growth Market Denmark as per 8 November 2024. New shares are issued due to a
directed issue of new shares.
Name: ... ► Artikel lesen | |
21.10.24 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 21.10.2024 | 751 | Xetra Newsboard | The following instruments on XETRA do have their first trading 21.10.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 21.10.2024
Aktien
1 AU000000ARB5 ARB Corporation Ltd.
2... ► Artikel lesen | |
14.10.24 | ViroGates A/S: ViroGates announces a distribution agreement with suPAR Health and a directed issue of shares to suPAR Remedy LLC | 241 | GlobeNewswire (Europe) | Company Announcement no. 8/2024 (October 14, 2024)
ViroGates announces an agreement with US-based suPAR Health to distribute its blood test for chronic inflammation within the United States. ViroGates... ► Artikel lesen | |
15.08.24 | ViroGates A/S: ViroGates announces its half-year report for H1 2024: Revenue for the first half-year of 2024 falls behind the same period in 2023 due to lower activity among research customers | 118 | GlobeNewswire (Europe) | Company Announcement no. 7/2024 (August 15, 2024)
Inside informationBIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for better... ► Artikel lesen | |
VIROGATES Aktie jetzt für 0€ handeln | |||||
17.07.24 | ViroGates A/S: ViroGates announces revised financial guidance for 2024 | 192 | GlobeNewswire (Europe) | Company Announcement no. 6/2024 (July 17, 2024)
Inside informationBIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for better triaging... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |